Literature DB >> 25952949

Anti-inflammatory effects of hinokitiol on human corneal epithelial cells: an in vitro study.

J Ye1, Y-F Xu1, L-X Lou1, K Jin1, Q Miao1, X Ye1, Y Xi1.   

Abstract

PURPOSE: This study assessed the anti-inflammatory effect and mechanism of action of hinokitiol in human corneal epithelial (HCE) cells.
METHODS: HCE cells were incubated with different concentrations of hinokitiol or dimethylsulfoxide (DMSO), which served as a vehicle control. Cell viability was evaluated using Cell Counting Kit-8 (CCK-8) assay. After polyriboinosinic:polyribocytidylic acid (poly(I:C)) stimulus, cells with or without hinokitiol were evaluated for the mRNA and protein levels of interleukin-8 (IL-8), interleukin-6 (IL-6), and interleukin-1β (IL-1β) using real-time PCR analysis and an enzyme-linked immunosorbent assay (ELISA), respectively. Nuclear and cytoplasmic levels of nuclear factor kappa B (NF-κB) p65 protein and an inhibitor of NF-κB α (IκBα) were evaluated using western blotting.
RESULTS: There were no significant differences among the treatment concentrations of hinokitiol compared with cells incubated in medium only. Incubating with 100 μM hinokitiol significantly decreased the mRNA levels of IL-8 to 58.77±10.41% (P<0.01), IL-6 to 64.64±12.71% (P<0.01), and IL-1β to 54.19±8.10% (P<0.01) compared with cells stimulated with poly(I:C) alone. The protein levels of IL-8, IL-6, and IL-1β had similar trend. Further analysis revealed that hinokitiol maintained the levels of IκBα and significantly reduced NF-κB p65 subunit translocation to the nucleus which significantly inhibiting the activation of the NF-κB signal pathway.
CONCLUSION: Hinokitiol showed a significant protective effect against ocular surface inflammation through inhibiting the NF-κB pathway, which may indicate the possibility to relieve the ocular surface inflammation of dry eye syndrome (DES).

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25952949      PMCID: PMC4506343          DOI: 10.1038/eye.2015.62

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  49 in total

1.  Rabbit conjunctival epithelium transports fluid, and P2Y2(2) receptor agonists stimulate Cl(-) and fluid secretion.

Authors:  Y Li; K Kuang; B Yerxa; Q Wen; H Rosskothen; J Fischbarg
Journal:  Am J Physiol Cell Physiol       Date:  2001-08       Impact factor: 4.249

Review 2.  Role of immunity and inflammation in corneal and ocular surface disease associated with dry eye.

Authors:  M Reza Dana; Pedram Hamrah
Journal:  Adv Exp Med Biol       Date:  2002       Impact factor: 2.622

3.  Triggering of TLR3 by polyI:C in human corneal epithelial cells to induce inflammatory cytokines.

Authors:  Mayumi Ueta; Junji Hamuro; Hiroshi Kiyono; Shigeru Kinoshita
Journal:  Biochem Biophys Res Commun       Date:  2005-05-27       Impact factor: 3.575

4.  Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.

Authors:  Laurie D Barber; Stephen C Pflugfelder; Joseph Tauber; Gary N Foulks
Journal:  Ophthalmology       Date:  2005-10       Impact factor: 12.079

Review 5.  Rationale for anti-inflammatory therapy in dry eye syndrome.

Authors:  C S de Paiva; S C Pflugfelder
Journal:  Arq Bras Oftalmol       Date:  2008 Nov-Dec       Impact factor: 0.872

Review 6.  Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia.

Authors:  A J Lee; J Lee; S-M Saw; G Gazzard; D Koh; D Widjaja; D T H Tan
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

7.  Desiccating stress induces T cell-mediated Sjögren's Syndrome-like lacrimal keratoconjunctivitis.

Authors:  Jerry Y Niederkorn; Michael E Stern; Stephen C Pflugfelder; Cintia S De Paiva; Rosa M Corrales; Jianping Gao; Karyn Siemasko
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

8.  Binding sites for human interleukin 1 alpha, gamma interferon and tumor necrosis factor on cultured fibroblasts of normal cornea and keratoconus.

Authors:  E J Fabre; J Bureau; Y Pouliquen; G Lorans
Journal:  Curr Eye Res       Date:  1991-07       Impact factor: 2.424

9.  Biological activity of alpha-thujaplicin, the isomer of hinokitiol.

Authors:  Yasuhiro Morita; Eiko Matsumura; Toshihiro Okabe; Toru Fukui; Mitsunobu Shibata; Masaaki Sugiura; Tatsuhiko Ohe; Hiroshi Tsujibo; Nakao Ishida; Yoshihiko Inamori
Journal:  Biol Pharm Bull       Date:  2004-06       Impact factor: 2.233

Review 10.  An alternative receptor to poly I:C on cell surfaces for interferon induction.

Authors:  Itsuro Yoshida; Masanobu Azuma
Journal:  Microbiol Immunol       Date:  2013-05       Impact factor: 1.955

View more
  5 in total

1.  Calcium Phosphate Cement with Antimicrobial Properties and Radiopacity as an Endodontic Material.

Authors:  Tzong-Ming Shieh; Shih-Ming Hsu; Kai-Chi Chang; Wen-Cheng Chen; Dan-Jae Lin
Journal:  Materials (Basel)       Date:  2017-10-31       Impact factor: 3.623

2.  Hinokitiol-Loaded Mesoporous Calcium Silicate Nanoparticles Induce Apoptotic Cell Death through Regulation of the Function of MDR1 in Lung Adenocarcinoma Cells.

Authors:  Yu-Fang Shen; Chia-Che Ho; Ming-You Shie; Kan Wang; Hsin-Yuan Fang
Journal:  Materials (Basel)       Date:  2016-04-25       Impact factor: 3.623

3.  Different Cell Responses to Hinokitiol Treatment Result in Senescence or Apoptosis in Human Osteosarcoma Cell Lines.

Authors:  Shun-Cheng Yang; Hsuan-Ying Chen; Wan-Ling Chuang; Hui-Chun Wang; Cheng-Pu Hsieh; Yi-Fu Huang
Journal:  Int J Mol Sci       Date:  2022-01-31       Impact factor: 5.923

4.  Nerve growth factor inhibits TLR3-induced inflammatory cascades in human corneal epithelial cells.

Authors:  Huiyu Chen; Jing Zhang; Yiqin Dai; Jianjiang Xu
Journal:  J Inflamm (Lond)       Date:  2019-12-26       Impact factor: 4.981

5.  Treatment of severe pneumonia by hinokitiol in a murine antimicrobial-resistant pneumococcal pneumonia model.

Authors:  Toshihito Isono; Hisanori Domon; Kosuke Nagai; Tomoki Maekawa; Hikaru Tamura; Takumi Hiyoshi; Katsunori Yanagihara; Eiji Kunitomo; Shoji Takenaka; Yuichiro Noiri; Yutaka Terao
Journal:  PLoS One       Date:  2020-10-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.